Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Genomics Regains Compliance with Nasdaq Listing Requirement

NEW YORK (GenomeWeb News) – Rosetta Genomics today said that it has regained compliance with a Nasdaq listing requirement regarding stockholders' equity.

The firm, which makes microRNA-based diagnostic products, said that it received notification from the Nasdaq Listing Qualifications Staff that it is now in compliance with a requirement that it have $2.5 million in stockholders' equity in order to remain listed on the Nasdaq Capital Market.

Last week, Rosetta said that it has regained compliance with another listing requirement — the $1 bid price for its stock. The firm recently effected a reverse one-for-15 reverse stock split, which was followed by a strong surge in its stock price.

It also announced last week that it had netted proceeds of about $6 million from a direct offering of 570,755 ordinary shares at $11.50 per share to certain investors.

In early Wednesday trade, shares of Rosetta were up 1 percent at $12.45.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.